Abstract:Introduction. Advances in sequencing technologies have enabled extensive genetic testing on an individual basis. Genome-wide association studies (GWAS) have provided insight into the pathophysiology of PD. Additionally, direct-to-consumer genetic testing has enabled the identification of genetic diseases and risk factors without genetic counselling. As genetics increasingly permeates clinical practice, this paper aims to summarise the most important information on genetics in PD forclinical practitioners. State-of-the-art. LRRK2 mutations may be found in c.1% of all PD patients with an indistinguishable phenotype from sporadic PD. LRRK2-PD is more prevalent in patients with a positive family history (5-6%) and among certain populations (e.g. up to 41% in North Africans and Ashkenazi Jews). Other familial forms include PRKN (patients with early onset, EOPD), VPS35 (Western European ancestry), PINK1 (EOPD), DJ-1 (EOPD), and SNCA. GBA mutations are found in a large number of PD patients and are associated with faster progression and a poorer prognosis. GWAS have identified 90 genetic risk variants for developing PD and several genetic modifiers for the age at onset, disease progression, and response to treatment. Clinical implications. Multigene panels using next-generation sequencing (NGS) are the first choice for genetic testing in clinical settings. Whole exome sequencing is increasingly being used, particularly as the second-tier testing in patients with negative results of multigene panels. NGS may not detect accurately copy number variants (CNV), meaning that additional analysis is warranted. In a case of a variant of unknown significance (VUS), we suggest firstly searching the up-to-date literature. Segregation studies and in silico predictions may shed more light on the character of the VUS; however, functional studies remain the gold standard. Several interventional clinical trials are active for carriers of LRRK2 and/or GBA mutations. Future directions. Application of artificial intelligence and machine learning will enable high-throughput analysis of large sets of multimodal data. We speculate that, in the future, the treatment landscape for PD will be similar to that in oncological conditions, in which the presence of certain gene mutations or gene overexpression determines the prognosis and treatment decision-making.

Recent advances in novel mutation genes of Parkinson's disease

The genetic background of Parkinson's disease: current progress and future prospects

Analysis of Rare Variants of Autosomal‐dominant Genes in a Chinese Population with Sporadic Parkinson’s Disease

Decoding the Role of Familial Parkinson’s Disease-Related Genes in DNA Damage and Repair

Genetic risk factors in Parkinson’s disease

Identification of Parkinson's Disease-Causing Genes Via Omics Data.

Genetics of Parkinson's Disease: state-of-the-art and role in clinical settings

Genetics in Parkinson’s disease, state-of-the-art and future perspectives

Genetic Insights into Sporadic Parkinson's Disease Pathogenesis

Advances in targeted therapies for Parkinson's disease

Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches

Joint-tissue integrative analysis identifies high-risk genes for Parkinson's disease

An Update on Potential Therapeutic Strategies for Parkinson’s Disease Based on Pathogenic Mechanisms

Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies

Polymorphism of neurodegeneration-related genes associated with Parkinson's disease risk

The Link Between the SNCA Gene and Parkinsonism

Genetic Factors Involved in the Pathogenesis of Parkinson's Disease

Genetic Imaging Of Neuroinflammation In Parkinson'S Disease: Recent Advancements

Impact of gene mutation in the development of Parkinson's disease

Genetic Imaging of Neuroinflammation in Parkinson’s Disease: Recent Advancements

Pathogenesis of Parkinson's disease: from hints from monogenic familial PD to biomarkers